
Vaccines
Latest News
Video Series

Latest Videos
Shorts










Podcasts
More News

With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.

Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.

In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.

The 18-year old resident of the state suffered from acute disseminated encephalomyelitis. Pennsylvania numbers are surging with some of the highest state totals of measles cases in the country.

The death was reported in Jefferson County where the coroner released a statement announcing it was in an unvaccinated woman.

FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax's partners, all reformulated to target the XFG variant, giving clinicians several options ahead of the fall respiratory virus season.

Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.

The Vaccine Integrity Project, in collaboration with the American Medical Association, conducted a vaccine and immunization effectiveness and safety review for RSV, Influenza, and COVID-19 for the 2026-2027 season. JAMA published the review, and here is an overview of the data going into this year's seasonal respiratory virus season.

GSK will advance its investigational mRNA seasonal flu vaccine candidate, which targets both hemagglutinin and neuraminidase, into a phase 3 trial in September 2026 after the shot outperformed licensed flu vaccines in a phase 2 study.

Here is a comprehensive list of vaccines approved this year as well as background information on the clinical data for each of them.

The FDA has approved formulations for the 2026-2027 vaccines including Pfizer-BioNTech's Comirnaty XFG, Novavax's commercial partners Sanofi and Takeda have secured approvals for its Nuvaxovid, and Moderna's Spikevax and mNEXSPIKE vaccines, all with protections against the currently circulating variant.

The FDA has approved Pfizer-BioNTech's 2026-2027 Comirnaty XFG formula, an updated COVID-19 vaccine targeting the XFG variant, for adults 65 and older and for individuals ages five through 64 with at least one high-risk underlying condition.

The phase 3 priMe trial found the investigational vaccine did not demonstrate noninferiority for preventing tuberculosis infection, though the study authors cited surrogate end point and exposure-imbalance issues that complicate interpretation.

The US childhood vaccine schedule was the big news this month with the presidential executive order making changes to it as well as the latest Centers for Disease Control and Prevention kindergarten immunization numbers for the 2025-2026 year. Learn more about the news with clinician commentary and how it might impact patient care.

The latest national numbers show a decrease in vaccination rates, along with a spike in the number of immunization exemptions, leading to an increase in the number of cases for vaccine-preventable diseases such as measles.

President Trump signed an order spacing the timing of immunizations, limiting the number of vaccines, and changing the MMR vaccine by separating it into 3 single-antigen vaccines.

The FDA has approved Moderna's influenza vaccine and set a Prescription Drug User Fee Act (PDUFA) date for Merck's RSV immunization product for expansion for a second season.

Investigational mRNA influenza vaccine prompts broader immune response than conventional vaccines, with activity against multiple strains.

An FDA advisory committee voted unanimously to recommend mRNA-1010 for approval, after the Agency initially refused to review the application and HHS cancelled contracts supporting mRNA vaccine development.

Two new complementary initiatives from CIDRAP’s Vaccine Integrity Project and The Evidence Collective aim to evaluate and improve US vaccine policymaking, governance, and public trust amid ongoing changes to the nation's immunization infrastructure.

There were a number of FDA approvals in recent weeks. Here is a listing of the approvals including the news reports and review of the phase 3 study data.

An investigational dual vaccine against Lassa fever and rabies demonstrates promise against priority target plaguing West Africa.

The FDA has approved an expanded indication for Merck's Capvaxive, allowing its use in children and adolescents aged 2 to 17 years with chronic medical conditions that increase their risk of pneumococcal disease following completion of a primary pneumococcal vaccination series.

New data on flu vaccine for children counter the contention that a lack of contemporaneous randomized data justifies its removal from recommended annual immunizations.

Modeling of the ACIP recommendation to replace universal birth-dose HepB vaccination with vaccination based on "shared decision" and maternal status shows substantially more maternal screening or vaccinating infants of unscreened mothers will be necessary to mitigate increase in infections.





































































































































































